<DOC>
	<DOCNO>NCT02431273</DOCNO>
	<brief_summary>This study evaluate hypothesis intravaginal ring ( IVRs ) safely sustained fashion , deliver antiretroviral ( ARV ) drug - tenofovir disoproxil fumarate ( TDF ) , emtricitabine ( FTC ) , maraviroc ( MVC ) , healthy woman use follow drug combination : 1 ) TDF ( `` Single '' IVR ) ; 2 ) TDF-FTC ( `` Dual '' IVR ) ; 3 ) TDF-FTC-MVC ( `` Triple '' IVR ) .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study HIV Prophylaxis Using Antiretroviral Intravaginal Rings Healthy Women</brief_title>
	<detailed_description>The broad long term goal project empower woman protect HIV woman-controlled sustain local delivery ARTs via intravaginal ring . The short-term general investigational plan evaluate IVRs release TDF , TDF-FTC TDF-FTC-MVC healthy woman 7 day open-label study determine safety drug concentration plasma cervicovaginal lavage secretion . Additional exploratory study consider plan base part result obtain study . The long-term investigational plan evaluate safety efficacy sustain release TDF , TDF-FTC TDF-FTC-MVC ability decrease HIV transmission vulnerable woman .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Provides write informed consent Healthy female 1845 year age HIV negative per subject report result screen examination Negative sexually transmit disease past 3 month screen exam No history genital herpes simplex I II per subject report Currently use contraception plan continue throughout study duration sex female Premenopausal regular menstrual cycle least 21 day menses history intermenstrual bleeding suppress menstrual cycle hormonal contraception DepoProvera continuous oral contraceptive agent Subjects must agree abstain vaginal , anal , oral sex throughout first week dose period use condom vaginal/rectal intercourse final visit use IVR Subjects must agree douche use vaginal product Single , Dual Triple ARV IVRs , include lubricant , feminine hygiene product , vaginal drying agent throughout dose period final visit Subjects must agree blood draw vaginal exam throughout course study HIV positive subject report result screen examination Positive history autoimmune disease Abnormal genital exam define grade 1 high adverse event DAIDS genital AE grade table Abnormal ALT AST Hepatitis B infection Active vaginal infection determine site IoR Abnormal renal function ( defined creatinine clearance &lt; 50mL/min/1.73 m2 ) Pregnant le 6 month postpartum current lactation Current use IVR ( i.e. , Nuvaring , Estring , Femring ) History TDF , FTC , MVC use and/or adverse reaction drug History adverse reaction silicone History toxic shock syndrome Currently receive chemotherapy immunosuppressive agent Use investigative drug within 30 day 5 halflives Currently use suspect use nontherapeutic injection drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TDF</keyword>
	<keyword>FTC</keyword>
	<keyword>MVC</keyword>
	<keyword>TDF-FTC</keyword>
	<keyword>TDF-FTC-MVC</keyword>
	<keyword>IVR</keyword>
	<keyword>ARV</keyword>
</DOC>